Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access ProgramTara C. Gangadhar, April K.S. Salama, Adil Daud et al.|Journal of Immunotherapy|2017Cited by 18
Safety and Efficacy of Pembrolizumab in US Patients Enrolled in KEYNOTE-030, an Expanded Access ProgramRomina P. Oxborough, April K.S. Salama, Tara C. Gangadhar et al.|Unknown|2015Cited by 0